Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease

被引:72
|
作者
Yamada, Hiroya [1 ]
Ohashi, Koji [2 ]
Suzuki, Koji [3 ]
Munetsuna, Eiji [4 ]
Ando, Yoshitaka [5 ]
Yamazaki, Mirai [2 ]
Ishikawa, Hiroaki [2 ]
Ichino, Naohiro [6 ]
Teradaira, Ryouji [2 ]
Hashimoto, Shuji [1 ]
机构
[1] Fujita Hlth Univ, Sch Med, Dept Hyg, Toyoake, Aichi 4701192, Japan
[2] Fujita Hlth Univ, Sch Hlth Sci, Dept Clin Biochem, Toyoake, Aichi 4701192, Japan
[3] Fujita Hlth Univ, Sch Hlth Sci, Dept Publ Hlth, Toyoake, Aichi 4701192, Japan
[4] Fujita Hlth Univ, Sch Med, Dept Biochem, Toyoake, Aichi 4701192, Japan
[5] Fujita Hlth Univ, Sch Med, Lab Clin Med, Dept Joint Res, Toyoake, Aichi 4701192, Japan
[6] Fujita Hlth Univ, Sch Hlth Sci, Dept Clin Physiol, Toyoake, Aichi 4701192, Japan
关键词
Circulating miRNA; miR-122; Non-alcoholic fatty liver disease; Serum miRNA; METABOLIC SYNDROME; MICRORNAS; PATHOGENESIS; BIOMARKERS; CANCER; SERUM;
D O I
10.1016/j.cca.2015.05.002
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Circulating microRNAs (miRs) may be promising biomarkers for several diseases. We previously found that miR-122 can function as a biomarker for non-alcoholic fatty liver disease (NAFLD). However, little is known regarding the time course of circulating miR-122 levels during the development of NAFLD. Here, we examined circulating miR-122 levels using a rat model of NAFLD. Methods: To clarify changes in serum levels of miR-122 during development of NAFLD, experimental rats were fed a high-fat diet (HFD) for 2-10 weeks, while control rats received standard chow. Serum and liver tissue was collected from all animals at 2, 6, and 10 weeks of feeding. Clinical laboratory parameters (cholesterol, TG, AST, ALT, NEFA) were determined by biochemistry analyzer. Hepatic lipid accumulation was estimated by Oil red 0 staining. Circulating miR-122 levels were then measured by real-time polymerase chain reaction. Results: Over the 10 weeks of feeding, body weight, total liver lipids, and liver and serum triacylglycerol were increased in the HFD group compared to the control group. However, no significant changes in serum alanine aminotransferase activity were observed, suggesting that NAFLD status was mild. In contrast, we observed drastic up-regulation of circulating miR-122 levels. Our findings suggest that serum miR-122 level is indeed useful for assessing early NAFLD and might be superior to clinical markers traditionally used to monitor hepatic disease. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:267 / 271
页数:5
相关论文
共 50 条
  • [31] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [32] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [33] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [34] Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan
    Norio Akuta
    Yusuke Kawamura
    Fumitaka Suzuki
    Satoshi Saitoh
    Yasuji Arase
    Hideo Kunimoto
    Yushi Sorin
    Shunichiro Fujiyama
    Hitomi Sezaki
    Tetsuya Hosaka
    Masahiro Kobayashi
    Yoshiyuki Suzuki
    Mariko Kobayashi
    Kenji Ikeda
    Hiromitsu Kumada
    Hepatology International, 2016, 10 : 647 - 656
  • [35] Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan
    Akuta, Norio
    Kawamura, Yusuke
    Suzuki, Fumitaka
    Saitoh, Satoshi
    Arase, Yasuji
    Kunimoto, Hideo
    Sorin, Yushi
    Fujiyama, Shunichiro
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Suzuki, Yoshiyuki
    Kobayashi, Mariko
    Ikeda, Kenji
    Kumada, Hiromitsu
    HEPATOLOGY INTERNATIONAL, 2016, 10 (04) : 647 - 656
  • [36] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [37] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [38] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [39] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [40] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15